Sedation – Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 46
Inquire Before Buying

Sedation – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Sedation – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sedation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sedation. Sedation – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sedation.
- A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sedation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sedation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Sedation – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Sedation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Sedation 7
Sedation Therapeutics under Development by Companies 9
Sedation Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Sedation Therapeutics - Products under Development by Companies 14
Sedation Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Sedation Therapeutics Development 16
AstraZeneca PLC 16
AcelRx Pharmaceuticals, Inc. 17
PAION AG 18
Mayne Pharma Limited 19
Sedation - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
CNS-7056 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
sufentanil + triazolam - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
zolpidem - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
propofol - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexmedetomidine hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Midazolam - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PF0713 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
flumazenil - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sedation Therapeutics - Drug Profile Updates 36
Sedation Therapeutics - Discontinued Products 38
Sedation Therapeutics - Dormant Products 39
Sedation - Product Development Milestones 40
Featured News & Press Releases 40
May 14, 2012: Ono Pharma Announces Phase II Study Results Of ONO-2745/CNS 7056 40
Oct 14, 2011: APP Pharmaceuticals Announces Increased Availability Of APP Diprivan And APP Propofol 1% 40
Jul 22, 2011: Orion Receives Positive CHMP Opinion For Dexdor 41
May 18, 2011: AcelRx Pharma Presents ARX-03 Clinical Study Results At 30th Annual Scientific Meeting Of American Pain Society 41
Nov 04, 2009: Paion Reports Positive Results Of Its Short Acting Anaesthetic/Sedative CNS 7056 In A Phase IIa Study In Upper GI Endoscopy 42
Apr 20, 2009: Paion Initiates Phase Ib Study Of The Anesthetic/Sedative CNS 7056 In Volunteers Undergoing Colonoscopy 43
Nov 19, 2008: Paion Announces Successful Completion Of Phase I Study With The Sedative/Anaesthetic CNS 7056 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Sedation, H2 2012 7
Products under Development for Sedation - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
AstraZeneca PLC, H2 2012 16
AcelRx Pharmaceuticals, Inc., H2 2012 17
PAION AG, H2 2012 18
Mayne Pharma Limited, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Sedation Therapeutics - Drug Profile Updates 36
Sedation Therapeutics - Discontinued Products 38
Sedation Therapeutics - Dormant Products 39

List of Figures
Number of Products under Development for Sedation, H2 2012 7
Products under Development for Sedation - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 – New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options
    Published: 29-Oct-2014        Price: US $4995 Onwards        
    GBI Research, a leading business intelligence provider, has released its latest research report: “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options”, which provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan......
  • Aortic Stent Grafts – Current and Future Players
    Published: 29-Oct-2014        Price: US $3500 Onwards        Pages: 106
    Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient’s native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated r......
  • Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma
    Published: 29-Oct-2014        Price: US $6995 Onwards        
    Large Degree of Innovation in NSCLC Pipeline The NSCLC pipeline currently has 389 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market comprises primarily ineffective chemotherapies that target tubulin or DNA replication, the pipeline shows an incredibly diverse range of therapies targeting multiple signaling pathways and molecules integral to cancer development. Thi......
  • Egypt Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 126
    BMI View: Egypt's relative political stability will lead to a pickup in growth over the coming quarters, increasing the attractiveness of the pharmaceutical market - for which our forecast has been revised slightly upwards. The government's increased emphasis on developing the pharmaceutical sector and the announced expansion of the Medicare healthcare programme are positive developments this quarter. The challenges faced by pharmaceutical companies wishing to operate in the market are the c......
  • Indonesia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 142
    BMI View: Indonesia is one of the most promising markets for the pharmaceutical and healthcare companies in South East Asia. The country's large population, positive economic outlook and considerable disease burden bode well for growth in demand for drugs, medical devices and healthcare services. The ongoing implementation of the universal healthcare scheme in Indonesia coupled with the impending launch of the ASEAN Economic Community will provide growth opportunities for pharmaceutical firm......
  • Moldova Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 93
    BMI View: The Moldovan pharmaceutical market presents limited opportunities for investors, given the market's total size and its reliance on out-of-pocket payments. The country's economic outlook, which is defined by its relations with Russia and the EU, will play a significant role in how the market grows over the coming years. Headline Expenditure Projections ? Pharmaceuticals: MDL2.73bn (USD214mn) in 2013 to MDL2.9bn (USD226mn) in 2014; +5.7% in local currency terms and +5.4% in US doll......
  • Sri Lanka Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 81
    BMI View: Sri Lanka's pharmaceutical sector has received investment from domestic and foreign - notably Indian - investors in recent years, as economic growth has picked up and the government focused on improving the domestic pharmaceutical sector. We therefore expect that pharmaceutical and healthcare sector growth will outpace economic growth over the five-year forecast period. Improved relations with India, after the country abstained from voting on the UNHCR resolution, are likely to spu......
  • 2014 Deep Research Report on Global and China Nalbuphine HCL Industry
    Published: 28-Oct-2014        Price: US $2200 Onwards        Pages: 121
    This is a professional and depth research report on Global and China Nalbuphine HCL industry. The report firstly introduced Nalbuphine HCL basic information included Nalbuphine HCL definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Nalbuphine HCL industry policy and plan, Nalbuphine HCL product specification, manufacturing process,......
  • 2014 Deep Research Report on Global and China Naltrexone HCL Industry
    Published: 28-Oct-2014        Price: US $2200 Onwards        Pages: 138
    This is a professional and depth research report on Global Naltrexone HCL industry. The report firstly introduced Naltrexone HCL basic information included Naltrexone HCL definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis. Global Regional (such as US Europe Asia China Japan etc regions) Global Leading Suppliers, different type products, different applications etc Naltrexone HCL production and market shar......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs